View ValuationArriVent BioPharma 将来の成長Future 基準チェック /26ArriVent BioPharma利益と収益がそれぞれ年間50.5%と58.2%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に-37.9% 51.2%なると予測されています。主要情報50.5%収益成長率51.17%EPS成長率Biotechs 収益成長25.2%収益成長率58.2%将来の株主資本利益率-37.91%アナリストカバレッジGood最終更新日19 May 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 12ArriVent BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.ArriVent BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $250 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offeringライブニュース • May 10ArriVent Secures FDA Clearance to Advance Dual-Target ADC for Ovarian and Endometrial CancerArriVent BioPharma received FDA clearance of its Investigational New Drug (IND) application for ARR-002, a tetravalent antibody-drug conjugate targeting MUC16 and NaPi2b. ARR-002 is initially aimed at treating ovarian and endometrial cancers, supported by preclinical data indicating dual-target binding, strong activity in animal models, and a favorable tolerability profile in monkeys. The company plans to start a Phase 1 clinical trial for ARR-002 and dose the first patient in the second half of 2026. For you as an investor, IND clearance is an important regulatory gate. It allows ArriVent to move ARR-002 from preclinical work into human studies, which is typically viewed as a key value inflection point in the drug development cycle. The dual-target approach to MUC16 and NaPi2b, together with the tetravalent design, is aimed at improving tumor targeting. The preclinical results provide the initial scientific rationale for advancing this candidate into the clinic. The planned Phase 1 trial and the target to dose the first patient in the second half of 2026 provide a rough sense of the development timeline, including when early safety and pharmacology data might start to emerge. As with any early-stage oncology asset, investors will likely focus on how quickly the trial initiates, the quality of the initial safety profile, and whether the biological activity seen in animal models is reflected in signals observed in patients with ovarian and endometrial cancers.お知らせ • May 09Arrivent Biopharma, Inc. Announces IND Clearance for ARR-002 Targeting Ovarian and Endometrial CancersArriVent BioPharma, Inc. announced clearance of an investigational new drug (IND) application by the United States Food and Drug Administration (FDA) for ARR-002, a potential first-in-class MUC16/NaPi2b targeting tetravalent antibody-drug conjugate (ADC) with an initial focus in ovarian and endometrial cancers and broader therapeutic potential across solid tumors. Phase 1 initiation is expected in the second half of 2026. At AACR, compelling preclinical data was presented demonstrating ARR-002’s potential to improve safety and efficacy over conventional single-target and bivalent bispecific ADCs in ovarian and endometrial cancers. ARR-002’s dual-target approach is designed to improve delivery and reduce off-tumor toxicity to overcome key limitations of single-target ADCs, including limited internalization, suboptimal payload delivery, and heterogeneous target expression. MUC16 and NaPi2b are highly expressed on ovarian and endometrial cancers with limited expression in normal tissues, making them strong co-targets. Select preclinical data included in the IND submission of ARR-002 was presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting in a joint presentation with Aarvik Therapeutics demonstrating: Effective binding to individual targets, simultaneous engagement of both targets, and enhanced internalization vs. single-target antibody controls; Superior in vivo efficacy vs. single-target ADCs in the OVCAR-3 xenograft model; The potential for a wider therapeutic window based on a favorable tolerability profile in cynomolgus monkeys, consisting of reversible hematologic findings at a higher maximum tolerated single dose vs. other approaches in development. ARR-002 (also known as AV-P138-ADC) is a first-in-class, Mucin-16 (MUC16) and sodium-dependent phosphate transport protein 2b (NaPi2b) dual-target, tetravalent (2+2 format) ADC, with site-specific conjugation to vcMMAE at a drug-to-antibody ratio (DAR) of 4. Both these cell surface antigens are expressed in ovarian and endometrial cancers with limited expression in normal tissues, making them strong co-targets.お知らせ • Apr 30ArriVent BioPharma, Inc., Annual General Meeting, Jun 18, 2026ArriVent BioPharma, Inc., Annual General Meeting, Jun 18, 2026.Seeking Alpha • Apr 29ArriVent BioPharma: A First AssessmentSummary ArriVent BioPharma (AVBP) is advancing firmonertinib for EGFR mutant NSCLC, targeting underserved Exon 20 and PACC mutations. AVBP awaits pivotal FURVENT trial data in mid-2026; positive results are critical, with market opportunity estimated just under $1 billion for Exon 20 globally. Competitive risk has increased following Dizal’s Zegfrovy Phase 3 success in the same indication, though detailed efficacy data remain undisclosed. A first assessment around ArriVent BioPharma follows in the paragraphs below. Read the full article on Seeking Alpha分析記事 • Nov 13Here's Why We're Watching ArriVent BioPharma's (NASDAQ:AVBP) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...お知らせ • Sep 23ArriVent BioPharma, Inc. Appoints Brent S. Rice as Chief Commercial OfficerArriVent BioPharma, Inc. announced the appointment of Brent S. Rice as Chief Commercial Officer (CCO). Mr. Rice joins ArriVent with over 25 years of U.S. and global commercial experience in the biotechnology and pharmaceutical industry. Before joining ArriVent, Brent most recently served as the Senior Vice President and global Chief Commercial Officer, and Managing Director U.S. at Autolus Therapeutics Ltd. where he led global commercialization, commercial strategy and business portfolio management of their early and late-stage pipeline of next generation therapies. Under Brent's leadership, the company transitioned from a clinical stage development company to a commercial organization where he built the U.S. organization and led the successful introduction and launch of Autolus' first commercial product. An experienced executive leader, Brent brings cross-functional expertise in marketing, operations, and reimbursement, and building scalable commercial organizations, leading product launches, and negotiating high-value agreements that improve patient access. Prior to Autolus, Brent led Managed Markets at Juno Therapeutics, where he developed payer and reimbursement strategy capabilities. He spent 18 years at Amgen in roles of increasing responsibility, earning recognition as a strong cross-functional leader driving innovative partnerships and portfolio success.お知らせ • Sep 09Arrivent BioPharma, Inc. Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung CancerArrivent BioPharma, Inc. presented positive final proof-of-concept data from the randomized global Phase 1b FURTHER trial for first-line firmonertinib monotherapy in patients with non-small cell lung cancer (NSCLC) harboring EGFR PACC mutations at the IASCLC 2025 annual World Conference on Lung Cancer (WCLC), in Barcelona, Spain. Firmonertinib was granted U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation for the treatment of patients with previously untreated locally advanced or metastatic non-squamous NSCLC with EGFR exon 20 insertion mutations.irmonertinib was also granted U.S. FDA Orphan Drug Designation for the treatment of NSCLC with EGFR mutations or human epidermal growth factor receptor 2 (HER2) mutations or HER4 mutations.お知らせ • Jul 22Arrivent Biopharma, Inc.'S Topline Pivotal Phase 3 Furvent Data for Firmonertinib in First-Line Nsclc Egfr Exon20 Insertion Mutations Is Projected to Be Early 2026ArriVent BioPharma, Inc. announced that topline firmonertinib monotherapy data from the global pivotal FURVENT Phase 3 (NCT05607550) study in first-line EGFR exon20 insertion mutant non-small cell lung cancer (NSCLC) is projected to be in early 2026. The primary endpoint will assess progression free survival (PFS) by blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. In the first quarter of 2025, the study completed enrollment across global sites. The FURVENT is a global, pivotal 3 arm Phase 3 clinical trial of firmonertinib in first-line non-squamous locally advanced or metastatic NSCLC patients with exon 20 insertion mutations being conducted jointly with partner Allist. The FURVENT clinical trial is designed to assess the safety and efficacy of firmonertinib administered at either 160 mg or 240 mg, once-daily with each dose being compared to platinum-based chemotherapy withemetrexed, the current first-line standard of care. The primary endpoint of this study is PFS by BICR per RECIST 1.1. Secondary endpoints in patients with brain metastases at baseline include brain-specific CNS overall response rate (CNS-ORR) and CNS-PFS by modified RECIST (mRECIST). The study enrolled 398 patients globally, including from sites in the United States, Europe and certain Asian countries including Japan and China. Firmonertinib is an oral, highly brain-penetrant, and broadly active mutation-selective epidermal growth factor receptor 2 (HER2) mutations or HER4 mutations. Firmonertinib was currently being studied in a global Phase 3 trial for first-line NSCLC patients with EGFR exon 20 insertion mutations (FURVENT; NCT05607550) and in a global Phase 3 study in first line NSCLC patients withEGFR PACC mutations (ALPACCA).お知らせ • Jul 02+ 1 more updateArriVent BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $75.000003 million.ArriVent BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $75.000003 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 2,482,692 Price\Range: $19.5 Discount Per Security: $1.17 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 1,363,469 Price\Range: $19.4999 Discount Per Security: $1.17お知らせ • Jun 30+ 5 more updatesArriVent BioPharma, Inc.(NasdaqGM:AVBP) dropped from Russell 2000 Value IndexArriVent BioPharma, Inc.(NasdaqGM:AVBP) dropped from Russell 2000 Value Indexお知らせ • Jun 24ArriVent Announces Positive Interim Firmonertinib Monotherapy Data from Global Phase 1B Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into A Global Pivotal StudyArriVent BioPharma, Inc. announced encouraging additional follow up proof-of-concept data from the randomized global Phase 1b FURTHER trial for first-line firmonertinib monotherapy in patients with non-small cell lung cancer (NSCLC) harboring EGFR PACC mutations and a clinical development update for the firmonertinib program for the treatment of EGFR PACC mutant NSCLC.分析記事 • May 21Is ArriVent BioPharma (NASDAQ:AVBP) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...お知らせ • Apr 29+ 1 more updateArriVent BioPharma, Inc., Annual General Meeting, Jun 18, 2025ArriVent BioPharma, Inc., Annual General Meeting, Jun 18, 2025.お知らせ • Feb 04ArriVent BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.ArriVent BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $250 million. Security Name: Common Shares Security Type: Common Stock Transaction Features: At the Market Offering分析記事 • Jan 11We're Not Very Worried About ArriVent BioPharma's (NASDAQ:AVBP) Cash Burn RateEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...分析記事 • Sep 24We Think ArriVent BioPharma (NASDAQ:AVBP) Can Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Seeking Alpha • Sep 17ArriVent BioPharma: Bringing A Novel Cancer Drug From ChinaSummary ArriVent BioPharma's lead molecule, firmonertinib, targets NSCLC with EGFR Exon 20 insertion mutations and shows potential in both classical and nonstandard EGFR mutations. Firmonertinib has demonstrated superior efficacy over first-generation TKIs and can cross the blood-brain barrier, showing promise for patients with brain metastases. With a market cap of $798mn and a cash balance sufficient for over 10 quarters, ArriVent is financially stable to continue its development. Upcoming catalysts include topline data from the phase 3 FURVENT trial in 2025, making firmonertinib a molecule worth watching in the nonstandard EGFRm space. Read the full article on Seeking Alphaお知らせ • Sep 10ArriVent BioPharma, Inc. Announces Positive Proof-Of-Concept Global Phase 1B Interim Data for Firmonertinib Monotherapy in First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At the 2024 World Conference on Lung CancerArriVent BioPharma, Inc. announced positive proof-of-concept randomized global Phase 1b FURTHER interim data for first-line firmonertinib monotherapy in patients with non-small cell lung cancer (NSCLC) harboring EGFR PACC mutations at a Presidential Symposium Presentation at the IASCLC 2024 annual World Conference on Lung Cancer (WCLC), in San Diego, California. ArriVent plans to host a virtual webinar on September 9, 2024 at 4:30 pm ET. Presidential Symposium Presentation Highlights Current standards of care have improved outcomes for classical EGFR mutations but have been less effective against uncommon EGFR mutation types including PACC and exon 20 insertion mutations which represent approximately 12% and 9% of NSCLC EGFR mutations, respectively. Firmonertinib, an oral, once-daily, highly brain-penetrant EGFR inhibitor with broad activity across EGFR mutations, was evaluated for interim clinical proof-of-concept data in first-line EGFR PACC mutant NSCLC as part of the Phase 1b FURTHER trial. Select clinical activity and safety results from FURTHER interim data analysis include: First clinical dataset from an EGFR inhibitor being tested in a randomized defined population of EGFR PACC mutant NSCLC Robust systemic and central nervous system (CNS) responses across patients observed as of June 20, 2024 (data cut): 81.8% at 240mg and 47.8% at 160mg overall response rate (ORR) by blinded independent central review (BICR) 63.6% and 34.8% confirmed ORR by BICR at 240mg and 160mg dose levels, respectively. One unconfirmed partial response pending confirmation at each of the 160mg and 240mg dose levels. Median duration of response had not yet been reached; 90.9% (n = 20/22) patients with confirmed responses remain on study 46.2% (n = 6/13) CNS confirmed ORR by modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by BICR in first-line patients with brain metastases at baseline Generally well-tolerated with a profile consistent with prior firmonertinib data Most frequent treatment-related adverse events (TRAEs) were diarrhea, rash, dry skin, stomatitis, and hepatic enzyme elevation No treatment discontinuation due to TRAEs was observed Firmonertinib showed promising dose-dependent activity in NSCLC patients across a broad range of EGFR PACC mutations in the first-line metastatic setting and includes CNS antitumor activity consistent with its high brain penetrance.お知らせ • May 18ArriVent BioPharma, Inc. Appoints John Hohneker as Board of DirectorsArriVent BioPharma, Inc. announced the appointment of John Hohneker, M.D. to its board of directors. Dr. Hohneker brings over 30 years of experience in biopharmaceutical leadership and drug development, and currently serves on the Boards of public companies Carisma Therapeutics, Inc. and Curis, Inc., and private companies Sonata Therapeutics and Trishula Therapeutics. Most recently, Dr. Hohneker served as President and Chief Executive Officer of Anokion SA. Prior to this role, Dr. Hohneker was President of Research and Development at Forma Therapeutics, Inc., where he guided the company’s transition from a discovery-stage biotech to a clinical-stage company. Previously, Dr. Hohneker held various leadership roles during his 14 years at Novartis AG, including Senior Vice President and Global Head of Development, Immunology and Dermatology. During his tenure at Novartis, he played a key role in the development, approval and commercialization of several products. Dr. Hohneker earned his B.A. in chemistry from Gettysburg College and his M.D. from the University of Medicine and Dentistry of New Jersey at Rutgers Medical School.お知らせ • Apr 24ArriVent BioPharma, Inc. Appoints Kristine Peterson to Its Board of DirectorsArriVent BioPharma, Inc. announced the appointment of Kristine Peterson to its Board of Directors. Ms. Peterson brings over 30 years of biopharmaceutical leadership experience, and currently serves on the Boards of public companies Immunocore, Inc. and Enanta Pharmaceuticals. Ms. Peterson has served as a Board Member for multiple companies, including ImmunoGen, Inc., Immunocore, Inc., Enanta Pharmaceuticals, Paratek Pharmaceuticals, Amarin Corporation and EyePoint Pharma. Most recently, she served as Chief Executive Officer for Valeritas, Inc., where she led the company’s development from early-stage R&D through to commercialization. Prior to Valeritas, Ms. Peterson held executive leadership roles at Johnson & Johnson, including Company Group Chair for their worldwide biotech and oncology groups, where she grew those businesses to more than $6 billion in sales, launched several new products, licensed new therapeutics, and rebuilt oncology R&D. Previously, she was also President and Senior Vice President, Commercial Operations for Biovail Corporation, where she oversaw the U.S. and Canadian business units. Earlier in her career, Ms. Peterson spent 20 years at Bristol-Myers Squibb in a variety of senior roles, including running their cardiovascular and metabolics business unit. She earned her B.S. and M.B. A from the University of Illinois at Urbana-Champaign.Seeking Alpha • Jan 29ArriVent Wows Investors With Promising China-Developed Lung Cancer TreatmentSummary ArriVent raised $150 million in an upsized IPO, marking one of the strongest performances for a China-linked IPO in New York over the last two years. The company has licensed global rights, excluding Greater China, to furmonertinib, a highly targeted drug used to treat non-small-cell lung cancer. In addition to furmonertinib, the company also has another cancer drug in its pipeline that it is co-developing with Aarvik, though that one is at a far earlier stage in its development. In terms of valuation, ArriVent should probably be ultimately valued at similar levels to Allist, which currently trades at a strong P/S multiple of 5 and an equally strong P/E ratio of 38. Read the full article on Seeking AlphaBoard Change • Jan 27High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. No experienced directors. No highly experienced directors. Co-Founder, President of Research & Development and Director Stuart Lutzker is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.業績と収益の成長予測NasdaqGM:AVBP - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2028136-90-99-108812/31/202742-168-140-136912/31/2026N/A-192-169-170103/31/2026N/A-145-134-134N/A12/31/2025N/A-166-161-161N/A9/30/2025N/A-151-146-146N/A6/30/2025N/A-137-127-127N/A3/31/2025N/A-127-120-120N/A12/31/2024N/A-80-70-70N/A9/30/2024N/A-81-69-69N/A6/30/2024N/A-75-68-68N/A3/31/2024N/A-75-58-58N/A12/31/2023N/A-69-56-56N/A9/30/2023N/A-59-57-57N/A6/30/2023N/A-56-51-51N/A3/31/2023N/A-42-52-52N/A12/31/2022N/A-37-44-44N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: AVBP今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: AVBP今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: AVBP今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: AVBPの収益 ( 58.2% ) US市場 ( 11.7% ) よりも速いペースで成長すると予測されています。高い収益成長: AVBPの収益 ( 58.2% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: AVBP 3 年以内に赤字になると予測されています。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 07:40終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋ArriVent BioPharma, Inc. 10 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。17 アナリスト機関Kalpit PatelB. Riley Securities, Inc.Mayank MamtaniB. Riley Securities, Inc.Suranjit MukherjeeBTIG14 その他のアナリストを表示
お知らせ • May 12ArriVent BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.ArriVent BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $250 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
ライブニュース • May 10ArriVent Secures FDA Clearance to Advance Dual-Target ADC for Ovarian and Endometrial CancerArriVent BioPharma received FDA clearance of its Investigational New Drug (IND) application for ARR-002, a tetravalent antibody-drug conjugate targeting MUC16 and NaPi2b. ARR-002 is initially aimed at treating ovarian and endometrial cancers, supported by preclinical data indicating dual-target binding, strong activity in animal models, and a favorable tolerability profile in monkeys. The company plans to start a Phase 1 clinical trial for ARR-002 and dose the first patient in the second half of 2026. For you as an investor, IND clearance is an important regulatory gate. It allows ArriVent to move ARR-002 from preclinical work into human studies, which is typically viewed as a key value inflection point in the drug development cycle. The dual-target approach to MUC16 and NaPi2b, together with the tetravalent design, is aimed at improving tumor targeting. The preclinical results provide the initial scientific rationale for advancing this candidate into the clinic. The planned Phase 1 trial and the target to dose the first patient in the second half of 2026 provide a rough sense of the development timeline, including when early safety and pharmacology data might start to emerge. As with any early-stage oncology asset, investors will likely focus on how quickly the trial initiates, the quality of the initial safety profile, and whether the biological activity seen in animal models is reflected in signals observed in patients with ovarian and endometrial cancers.
お知らせ • May 09Arrivent Biopharma, Inc. Announces IND Clearance for ARR-002 Targeting Ovarian and Endometrial CancersArriVent BioPharma, Inc. announced clearance of an investigational new drug (IND) application by the United States Food and Drug Administration (FDA) for ARR-002, a potential first-in-class MUC16/NaPi2b targeting tetravalent antibody-drug conjugate (ADC) with an initial focus in ovarian and endometrial cancers and broader therapeutic potential across solid tumors. Phase 1 initiation is expected in the second half of 2026. At AACR, compelling preclinical data was presented demonstrating ARR-002’s potential to improve safety and efficacy over conventional single-target and bivalent bispecific ADCs in ovarian and endometrial cancers. ARR-002’s dual-target approach is designed to improve delivery and reduce off-tumor toxicity to overcome key limitations of single-target ADCs, including limited internalization, suboptimal payload delivery, and heterogeneous target expression. MUC16 and NaPi2b are highly expressed on ovarian and endometrial cancers with limited expression in normal tissues, making them strong co-targets. Select preclinical data included in the IND submission of ARR-002 was presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting in a joint presentation with Aarvik Therapeutics demonstrating: Effective binding to individual targets, simultaneous engagement of both targets, and enhanced internalization vs. single-target antibody controls; Superior in vivo efficacy vs. single-target ADCs in the OVCAR-3 xenograft model; The potential for a wider therapeutic window based on a favorable tolerability profile in cynomolgus monkeys, consisting of reversible hematologic findings at a higher maximum tolerated single dose vs. other approaches in development. ARR-002 (also known as AV-P138-ADC) is a first-in-class, Mucin-16 (MUC16) and sodium-dependent phosphate transport protein 2b (NaPi2b) dual-target, tetravalent (2+2 format) ADC, with site-specific conjugation to vcMMAE at a drug-to-antibody ratio (DAR) of 4. Both these cell surface antigens are expressed in ovarian and endometrial cancers with limited expression in normal tissues, making them strong co-targets.
お知らせ • Apr 30ArriVent BioPharma, Inc., Annual General Meeting, Jun 18, 2026ArriVent BioPharma, Inc., Annual General Meeting, Jun 18, 2026.
Seeking Alpha • Apr 29ArriVent BioPharma: A First AssessmentSummary ArriVent BioPharma (AVBP) is advancing firmonertinib for EGFR mutant NSCLC, targeting underserved Exon 20 and PACC mutations. AVBP awaits pivotal FURVENT trial data in mid-2026; positive results are critical, with market opportunity estimated just under $1 billion for Exon 20 globally. Competitive risk has increased following Dizal’s Zegfrovy Phase 3 success in the same indication, though detailed efficacy data remain undisclosed. A first assessment around ArriVent BioPharma follows in the paragraphs below. Read the full article on Seeking Alpha
分析記事 • Nov 13Here's Why We're Watching ArriVent BioPharma's (NASDAQ:AVBP) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
お知らせ • Sep 23ArriVent BioPharma, Inc. Appoints Brent S. Rice as Chief Commercial OfficerArriVent BioPharma, Inc. announced the appointment of Brent S. Rice as Chief Commercial Officer (CCO). Mr. Rice joins ArriVent with over 25 years of U.S. and global commercial experience in the biotechnology and pharmaceutical industry. Before joining ArriVent, Brent most recently served as the Senior Vice President and global Chief Commercial Officer, and Managing Director U.S. at Autolus Therapeutics Ltd. where he led global commercialization, commercial strategy and business portfolio management of their early and late-stage pipeline of next generation therapies. Under Brent's leadership, the company transitioned from a clinical stage development company to a commercial organization where he built the U.S. organization and led the successful introduction and launch of Autolus' first commercial product. An experienced executive leader, Brent brings cross-functional expertise in marketing, operations, and reimbursement, and building scalable commercial organizations, leading product launches, and negotiating high-value agreements that improve patient access. Prior to Autolus, Brent led Managed Markets at Juno Therapeutics, where he developed payer and reimbursement strategy capabilities. He spent 18 years at Amgen in roles of increasing responsibility, earning recognition as a strong cross-functional leader driving innovative partnerships and portfolio success.
お知らせ • Sep 09Arrivent BioPharma, Inc. Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung CancerArrivent BioPharma, Inc. presented positive final proof-of-concept data from the randomized global Phase 1b FURTHER trial for first-line firmonertinib monotherapy in patients with non-small cell lung cancer (NSCLC) harboring EGFR PACC mutations at the IASCLC 2025 annual World Conference on Lung Cancer (WCLC), in Barcelona, Spain. Firmonertinib was granted U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation for the treatment of patients with previously untreated locally advanced or metastatic non-squamous NSCLC with EGFR exon 20 insertion mutations.irmonertinib was also granted U.S. FDA Orphan Drug Designation for the treatment of NSCLC with EGFR mutations or human epidermal growth factor receptor 2 (HER2) mutations or HER4 mutations.
お知らせ • Jul 22Arrivent Biopharma, Inc.'S Topline Pivotal Phase 3 Furvent Data for Firmonertinib in First-Line Nsclc Egfr Exon20 Insertion Mutations Is Projected to Be Early 2026ArriVent BioPharma, Inc. announced that topline firmonertinib monotherapy data from the global pivotal FURVENT Phase 3 (NCT05607550) study in first-line EGFR exon20 insertion mutant non-small cell lung cancer (NSCLC) is projected to be in early 2026. The primary endpoint will assess progression free survival (PFS) by blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. In the first quarter of 2025, the study completed enrollment across global sites. The FURVENT is a global, pivotal 3 arm Phase 3 clinical trial of firmonertinib in first-line non-squamous locally advanced or metastatic NSCLC patients with exon 20 insertion mutations being conducted jointly with partner Allist. The FURVENT clinical trial is designed to assess the safety and efficacy of firmonertinib administered at either 160 mg or 240 mg, once-daily with each dose being compared to platinum-based chemotherapy withemetrexed, the current first-line standard of care. The primary endpoint of this study is PFS by BICR per RECIST 1.1. Secondary endpoints in patients with brain metastases at baseline include brain-specific CNS overall response rate (CNS-ORR) and CNS-PFS by modified RECIST (mRECIST). The study enrolled 398 patients globally, including from sites in the United States, Europe and certain Asian countries including Japan and China. Firmonertinib is an oral, highly brain-penetrant, and broadly active mutation-selective epidermal growth factor receptor 2 (HER2) mutations or HER4 mutations. Firmonertinib was currently being studied in a global Phase 3 trial for first-line NSCLC patients with EGFR exon 20 insertion mutations (FURVENT; NCT05607550) and in a global Phase 3 study in first line NSCLC patients withEGFR PACC mutations (ALPACCA).
お知らせ • Jul 02+ 1 more updateArriVent BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $75.000003 million.ArriVent BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $75.000003 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 2,482,692 Price\Range: $19.5 Discount Per Security: $1.17 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 1,363,469 Price\Range: $19.4999 Discount Per Security: $1.17
お知らせ • Jun 30+ 5 more updatesArriVent BioPharma, Inc.(NasdaqGM:AVBP) dropped from Russell 2000 Value IndexArriVent BioPharma, Inc.(NasdaqGM:AVBP) dropped from Russell 2000 Value Index
お知らせ • Jun 24ArriVent Announces Positive Interim Firmonertinib Monotherapy Data from Global Phase 1B Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into A Global Pivotal StudyArriVent BioPharma, Inc. announced encouraging additional follow up proof-of-concept data from the randomized global Phase 1b FURTHER trial for first-line firmonertinib monotherapy in patients with non-small cell lung cancer (NSCLC) harboring EGFR PACC mutations and a clinical development update for the firmonertinib program for the treatment of EGFR PACC mutant NSCLC.
分析記事 • May 21Is ArriVent BioPharma (NASDAQ:AVBP) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
お知らせ • Apr 29+ 1 more updateArriVent BioPharma, Inc., Annual General Meeting, Jun 18, 2025ArriVent BioPharma, Inc., Annual General Meeting, Jun 18, 2025.
お知らせ • Feb 04ArriVent BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.ArriVent BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $250 million. Security Name: Common Shares Security Type: Common Stock Transaction Features: At the Market Offering
分析記事 • Jan 11We're Not Very Worried About ArriVent BioPharma's (NASDAQ:AVBP) Cash Burn RateEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Sep 24We Think ArriVent BioPharma (NASDAQ:AVBP) Can Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Sep 17ArriVent BioPharma: Bringing A Novel Cancer Drug From ChinaSummary ArriVent BioPharma's lead molecule, firmonertinib, targets NSCLC with EGFR Exon 20 insertion mutations and shows potential in both classical and nonstandard EGFR mutations. Firmonertinib has demonstrated superior efficacy over first-generation TKIs and can cross the blood-brain barrier, showing promise for patients with brain metastases. With a market cap of $798mn and a cash balance sufficient for over 10 quarters, ArriVent is financially stable to continue its development. Upcoming catalysts include topline data from the phase 3 FURVENT trial in 2025, making firmonertinib a molecule worth watching in the nonstandard EGFRm space. Read the full article on Seeking Alpha
お知らせ • Sep 10ArriVent BioPharma, Inc. Announces Positive Proof-Of-Concept Global Phase 1B Interim Data for Firmonertinib Monotherapy in First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At the 2024 World Conference on Lung CancerArriVent BioPharma, Inc. announced positive proof-of-concept randomized global Phase 1b FURTHER interim data for first-line firmonertinib monotherapy in patients with non-small cell lung cancer (NSCLC) harboring EGFR PACC mutations at a Presidential Symposium Presentation at the IASCLC 2024 annual World Conference on Lung Cancer (WCLC), in San Diego, California. ArriVent plans to host a virtual webinar on September 9, 2024 at 4:30 pm ET. Presidential Symposium Presentation Highlights Current standards of care have improved outcomes for classical EGFR mutations but have been less effective against uncommon EGFR mutation types including PACC and exon 20 insertion mutations which represent approximately 12% and 9% of NSCLC EGFR mutations, respectively. Firmonertinib, an oral, once-daily, highly brain-penetrant EGFR inhibitor with broad activity across EGFR mutations, was evaluated for interim clinical proof-of-concept data in first-line EGFR PACC mutant NSCLC as part of the Phase 1b FURTHER trial. Select clinical activity and safety results from FURTHER interim data analysis include: First clinical dataset from an EGFR inhibitor being tested in a randomized defined population of EGFR PACC mutant NSCLC Robust systemic and central nervous system (CNS) responses across patients observed as of June 20, 2024 (data cut): 81.8% at 240mg and 47.8% at 160mg overall response rate (ORR) by blinded independent central review (BICR) 63.6% and 34.8% confirmed ORR by BICR at 240mg and 160mg dose levels, respectively. One unconfirmed partial response pending confirmation at each of the 160mg and 240mg dose levels. Median duration of response had not yet been reached; 90.9% (n = 20/22) patients with confirmed responses remain on study 46.2% (n = 6/13) CNS confirmed ORR by modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by BICR in first-line patients with brain metastases at baseline Generally well-tolerated with a profile consistent with prior firmonertinib data Most frequent treatment-related adverse events (TRAEs) were diarrhea, rash, dry skin, stomatitis, and hepatic enzyme elevation No treatment discontinuation due to TRAEs was observed Firmonertinib showed promising dose-dependent activity in NSCLC patients across a broad range of EGFR PACC mutations in the first-line metastatic setting and includes CNS antitumor activity consistent with its high brain penetrance.
お知らせ • May 18ArriVent BioPharma, Inc. Appoints John Hohneker as Board of DirectorsArriVent BioPharma, Inc. announced the appointment of John Hohneker, M.D. to its board of directors. Dr. Hohneker brings over 30 years of experience in biopharmaceutical leadership and drug development, and currently serves on the Boards of public companies Carisma Therapeutics, Inc. and Curis, Inc., and private companies Sonata Therapeutics and Trishula Therapeutics. Most recently, Dr. Hohneker served as President and Chief Executive Officer of Anokion SA. Prior to this role, Dr. Hohneker was President of Research and Development at Forma Therapeutics, Inc., where he guided the company’s transition from a discovery-stage biotech to a clinical-stage company. Previously, Dr. Hohneker held various leadership roles during his 14 years at Novartis AG, including Senior Vice President and Global Head of Development, Immunology and Dermatology. During his tenure at Novartis, he played a key role in the development, approval and commercialization of several products. Dr. Hohneker earned his B.A. in chemistry from Gettysburg College and his M.D. from the University of Medicine and Dentistry of New Jersey at Rutgers Medical School.
お知らせ • Apr 24ArriVent BioPharma, Inc. Appoints Kristine Peterson to Its Board of DirectorsArriVent BioPharma, Inc. announced the appointment of Kristine Peterson to its Board of Directors. Ms. Peterson brings over 30 years of biopharmaceutical leadership experience, and currently serves on the Boards of public companies Immunocore, Inc. and Enanta Pharmaceuticals. Ms. Peterson has served as a Board Member for multiple companies, including ImmunoGen, Inc., Immunocore, Inc., Enanta Pharmaceuticals, Paratek Pharmaceuticals, Amarin Corporation and EyePoint Pharma. Most recently, she served as Chief Executive Officer for Valeritas, Inc., where she led the company’s development from early-stage R&D through to commercialization. Prior to Valeritas, Ms. Peterson held executive leadership roles at Johnson & Johnson, including Company Group Chair for their worldwide biotech and oncology groups, where she grew those businesses to more than $6 billion in sales, launched several new products, licensed new therapeutics, and rebuilt oncology R&D. Previously, she was also President and Senior Vice President, Commercial Operations for Biovail Corporation, where she oversaw the U.S. and Canadian business units. Earlier in her career, Ms. Peterson spent 20 years at Bristol-Myers Squibb in a variety of senior roles, including running their cardiovascular and metabolics business unit. She earned her B.S. and M.B. A from the University of Illinois at Urbana-Champaign.
Seeking Alpha • Jan 29ArriVent Wows Investors With Promising China-Developed Lung Cancer TreatmentSummary ArriVent raised $150 million in an upsized IPO, marking one of the strongest performances for a China-linked IPO in New York over the last two years. The company has licensed global rights, excluding Greater China, to furmonertinib, a highly targeted drug used to treat non-small-cell lung cancer. In addition to furmonertinib, the company also has another cancer drug in its pipeline that it is co-developing with Aarvik, though that one is at a far earlier stage in its development. In terms of valuation, ArriVent should probably be ultimately valued at similar levels to Allist, which currently trades at a strong P/S multiple of 5 and an equally strong P/E ratio of 38. Read the full article on Seeking Alpha
Board Change • Jan 27High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. No experienced directors. No highly experienced directors. Co-Founder, President of Research & Development and Director Stuart Lutzker is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.